The custom antibody market is projected to grow at a CAGR of approximately 10% throughout the forecast period. This expansion is driven by increasing R&D activity, rising demand for highly specific ...
Pharmaceutical companies already use artificial intelligence for tasks like optimizing clinical trials, identifying drug targets and developing predictive models for risk detection. But AI’s next ...
OncoNano Medicine, Inc. ("OncoNano"), a clinical-stage biotechnology company developing precision therapies using its proprietary nanotechnology platform, today announced it will present new ...
Chemokines, acting as "traffic controllers" in the tumor microenvironment, regulate immune cell infiltration and local ...
Biomarkers are redefining how oncology trials are designed, shifting from single-mutation targeting to comprehensive genomic ...
Zai Lab Limited today announced clinical data indicating zocilurtatug pelitecan (zoci, formerly ZL-1310), a DLL3-targeting antibody-drug conjugate (ADC), provides rapid and robust intracranial ...
The world's most powerful supercomputer isn't just incredibly capable, it's also the largest one in the U.S. — at least, if ...
The theory behind antibody drug conjugates (ADCs) is simple yet elegant: by combining the specificity of a monoclonal antibody with the cytotoxicity of a potent small molecule drug, ADCs can precisely ...
Antibody drug conjugates (ADCs) are advancing through clinical development with increasing complexity in both formulation and ...
A handful of antibody-based extracellular targeted protein degraders are advancing in the clinic, highlighting emerging ...
HIV-1 envelope glycoprotein (Env), a gp120–gp41 trimer, undergoes coordinated conformational changes that drive membrane fusion and allow immune evasion by transiently concealing ...
New! Sign up for our free email newsletter.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results